NASDAQ:BIOT Biotech Acquisition (BIOT) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free BIOT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.14▼$10.1950-Day Range$10.08▼$10.3252-Week Range$8.30▼$10.41Volume44,400 shsAverage Volume244,605 shsMarket Capitalization$291.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biotech Acquisition alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Biotech Acquisition Stock (NASDAQ:BIOT)Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Read More Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here BIOT Stock News HeadlinesMay 3, 2024 | finance.yahoo.comEphicacy Consulting Group Completes Acquisition of Advance Research AssociatesMay 2, 2024 | bizjournals.comHow Moderna's cost-cutting moves hit a Bay Area biotechMay 3, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.May 1, 2024 | bizjournals.comAccounting giant wants to grow Albany footprint after Nuvalence acquisitionApril 29, 2024 | msn.comDeciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO PharmaceuticalApril 29, 2024 | markets.businessinsider.comDeciphera Up In Pre-market On News Of Acquisition By ONO Pharmaceutical For About $2.4 BlnApril 26, 2024 | msn.comEli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscapeApril 26, 2024 | finanznachrichten.deSagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.May 3, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 26, 2024 | markets.businessinsider.comBuy Rating on Danaher: Strong Biotech Performance and Growth Potential Despite Market ChallengesApril 26, 2024 | msn.comPhiladelphia-based Century Therapeutics Acquires Boston Biotechnology Firm Clade TherapeuticsApril 25, 2024 | msn.comImproved US biotech funding to aid FY25 growth, expects Jonathan Hunt, MD & CEO, Syngene InternationalApril 24, 2024 | msn.comPharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thriveApril 24, 2024 | finance.yahoo.comIMCD Spain expands its Pharmaceuticals presence with the acquisition of CobapharmaApril 22, 2024 | msn.comMBK Partners acquires pharmaceutical wholesaler Geo-Young from BlackstoneApril 19, 2024 | bizjournals.comSpark co-founder, Harvard professor launch Watertown biotech with $54MApril 19, 2024 | seekingalpha.comXBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF ForeverApril 18, 2024 | msn.comSan Diego biotech company making melanoma test patch cuts 56% of its workforceApril 18, 2024 | finance.yahoo.comStramsen Biotech Joins Elite Class of Unicorns at $6.5 Billion Valuation and a Potential Reverse Merger DealApril 17, 2024 | finance.yahoo.comEssential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral CapsulesApril 16, 2024 | finance.yahoo.comPharmAlliance Announces Acquisition of CHEORSApril 15, 2024 | finance.yahoo.comGlobal Directory Unveils Top 1,000 Pharmaceutical and Biotechnology Companies for 2024April 12, 2024 | bizjournals.comEliem pursues acquisition of New Jersey biotech after halting programsApril 11, 2024 | finance.yahoo.comVertex Pharmaceuticals Incorporated: Vertex: $4.9 Billion Acquisition of Alpine Immune Sciences Expands Kidney-Disease PortfolioApril 10, 2024 | marketwatch.comVera Therapeutics Shares Rise 9.9% After Alpine AcquisitionApril 10, 2024 | bizjournals.comVertex to acquire Seattle biotech for $4.9BApril 10, 2024 | msn.comVertex buying Seattle biotech for $4.9 billion, its biggest acquisition everSee More Headlines Receive BIOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotech Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOT CUSIPN/A CIK1825413 Webbioacq.com Phone212-227-1905FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.22% Return on Assets3.48% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-10.68Miscellaneous Outstanding Shares28,750,000Free Float23,288,000Market Cap$291.81 million OptionableNot Optionable Beta-0.12 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Michael Shleifer Ph.D. (Age 48)Chairman & CEO Mr. Thomas Fratacci (Age 44)CFO & Treasurer Mr. Ivan Jarry (Age 44)Chief Operating Officer Mr. Albert F. Hummel M.B.A. (Age 76)Chief Investment Officer & Director Key CompetitorsESSA PharmaNASDAQ:EPIXVerrica PharmaceuticalsNASDAQ:VRCAXOMANASDAQ:XOMAEnanta PharmaceuticalsNASDAQ:ENTAInozyme PharmaNASDAQ:INZYView All Competitors This page (NASDAQ:BIOT) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotech Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
